Blackstone, Carlyle, H&F Win Deal of the Year for Medline's $7.2B IPO

Blackstone, Carlyle Group, and Hellman & Friedman have claimed PE Hub's 2025 Overall Deal of the Year award for orchestrating Medline Industries' $7.2 billion initial public offering — a rare mega-exit that rewarded patience, operational discipline, and impeccable timing in one of private equity's most scrutinized sectors.

The Medline IPO, completed in October 2024, stands as the fourth-largest U.S. listing of the year and the biggest private equity-backed healthcare exit since the pandemic reshaped capital markets. For the three sponsors — who acquired the medical supply distributor in a $34 billion leveraged buyout back in 2021 — the public offering delivered validated their thesis that a century-old, family-controlled business could be professionalized, scaled, and brought to market even as rising rates hammered growth-stage valuations.

The recognition, announced at PE Hub's annual awards ceremony in New York, underscores a deal that checked nearly every box investors look for in a successful exit: outperformance against projections, operational transformation, strategic positioning within a resilient end market, and — crucially — an exit that actually happened when most IPO windows stayed firmly shut.

But the deal's success wasn't preordained. Medline's path to the public markets involved navigating supply chain chaos, absorbing inflationary cost pressures, and convincing institutional investors that a distributor of surgical gloves and hospital gowns deserved a premium valuation in an era when healthcare IPOs were quietly dying in registration.

When Blackstone, Carlyle, and Hellman & Friedman announced their take-private of Medline Industries in June 2021, the deal raised eyebrows. At $34 billion in enterprise value, it ranked as one of the largest LBOs in history. The target: a 108-year-old, Northfield, Illinois-based distributor of medical supplies that had remained family-owned through three generations and multiple recessions.

Medline wasn't broken. It was profitable, generated strong cash flow, and served over 300,000 customers across acute care, post-acute care, and surgery center facilities. But it lacked the operational rigor, technology backbone, and capital structure that institutional buyers believed could unlock significant value. The Mills family, which had controlled the company since its founding, was ready for liquidity. The PE consortium was ready to write the check.

The three firms split ownership roughly evenly, each bringing complementary expertise: Blackstone's operational playbook and healthcare portfolio depth, Carlyle's industrial and supply chain transformation experience, and Hellman & Friedman's track record in scaling founder-led companies into institutional-grade businesses. They committed to keeping management largely intact while injecting new finance, technology, and procurement leadership.

Then came the hard part. Within six months of closing, the consortium confronted pandemic aftershocks that sent input costs soaring and turned medical supply chains into battlegrounds. Hospitals consolidated. Competitors consolidated. And inflation — the quiet killer of leveraged balance sheets — started climbing.

The sponsors' strategy didn't rely on financial engineering. Instead, they executed a classic private equity value creation playbook: professionalize operations, invest in automation, rationalize the SKU base, and consolidate fragmented distribution networks. Nothing sexy. Everything effective.

Between 2021 and 2024, Medline rolled out warehouse automation across its 40+ distribution centers, cutting order fulfillment times and labor costs. It invested heavily in data infrastructure, implementing advanced analytics for demand forecasting and inventory optimization — critical when you're managing over 350,000 SKUs. The company also pruned low-margin product lines and renegotiated supplier contracts, boosting gross margins by approximately 150 basis points over the hold period.

Revenue growth stayed consistent. Medline posted approximately $20 billion in annual revenue in 2023, up from roughly $17.5 billion at acquisition. More importantly, EBITDA margins expanded from the low-teens to the mid-teens — a meaningful shift in a business where every percentage point of margin translates to hundreds of millions in enterprise value.

The sponsors also made two strategic acquisitions during the hold period, bringing in complementary surgical and wound care product lines that deepened Medline's relationships with IDN (integrated delivery network) customers. Those bolt-ons, relatively small in dollar terms, expanded Medline's addressable market and gave the company more negotiating leverage with both suppliers and buyers.

By mid-2024, the sponsors faced a choice: hold longer and wait for rates to fall, pursue a dividend recap, or test the public markets despite a hostile IPO environment. They chose the third option — but with caution.

Medline filed its S-1 registration statement in August 2024, initially targeting a valuation range of $40-45 billion. The filing revealed a business growing revenue at 8-10% annually, generating over $2 billion in annual EBITDA, and carrying a debt load of approximately $18 billion — manageable but meaningful given the interest rate environment.

Investor feedback during the roadshow was mixed. Institutional buyers liked the recurring revenue model, the sticky customer relationships, and the essential nature of the products. They worried about leverage, competitive pressures from Amazon's healthcare push, and whether a distributor could command growth multiples in a value-oriented market.

The sponsors adjusted. They priced the IPO at $24 per share in October 2024 — below the initial range but above the most conservative estimates — raising $7.2 billion in proceeds and valuing the company at roughly $42 billion post-money. The three PE firms retained majority ownership but created enough float to satisfy NYSE listing requirements and give institutional investors a meaningful stake.

The stock opened at $25.50 on its first day of trading and closed the first week at $26.75 — a modest but real pop that signaled genuine investor demand, not just book-building desperation. By year-end 2024, shares traded in the $27-29 range, giving the sponsors paper gains on their remaining stakes and validating the exit timing.

Most private equity-backed IPOs in 2024 either got pulled or priced below expectations. So why did Medline succeed? Three reasons stand out.

Medline sells products hospitals can't stop buying. Surgical gloves, wound dressings, hospital beds, IV supplies — the demand curve doesn't bend with consumer sentiment. Even during recessions, healthcare spending on consumables stays relatively stable. That predictability matters when institutional investors are pricing risk into every growth assumption.

The company's customer base is sticky. Hospitals don't switch distributors lightly. Procurement contracts run multi-year. Medline's top 100 customers have an average relationship tenure exceeding 15 years. That kind of revenue visibility is rare in private equity exits, and it showed up in the valuation.

Competitors like McKesson and Cardinal Health are public, providing clear valuation comparables. Medline priced roughly in line with those peers on an EV/EBITDA basis, which made the deal easier for investors to underwrite. There was no need to invent a new valuation framework or convince the market that a healthcare distributor deserved SaaS multiples.

The sponsors also timed the exit well. They avoided the 2022-2023 IPO drought when zero mega-cap deals priced. By October 2024, rate cut expectations were rising, equity markets had stabilized, and a few large IPOs — including Reddit and Klarna's secondary offerings — had performed reasonably. The window was open, but only slightly. Medline walked through it before it closed again.

The deal structure helped too. Unlike many PE-backed IPOs that feel like pure financial exits, Medline's offering included a commitment from the sponsors to retain majority ownership and stay involved in governance. That signaled confidence and reduced the perception that this was just a liquidity grab before problems emerged.

For all the success, this wasn't a home run in traditional venture capital terms. The sponsors bought at $34 billion and exited at $42 billion — a roughly 24% gross return over three years, or about 7-8% IRR before fees and carry. Respectable, especially in a difficult exit market, but not the 3x+ returns that define legendary deals.

Some observers argue the sponsors left value on the table by pricing conservatively. Had they waited another 6-12 months for rates to fall further or for the IPO market to fully reopen, Medline might have commanded a $45-50 billion valuation. But that calculus ignores the risk of waiting: what if the window closed entirely? What if a recession hit and hospitals cut spending? What if leverage costs kept climbing and ate into equity value?

PE Hub's Overall Deal of the Year award, announced at the firm's annual awards ceremony in New York on January 16, 2025, recognizes transactions that demonstrate excellence across execution, value creation, and market impact. Past winners include Vista Equity Partners' take-private of Pluralsight, KKR's acquisition of Envision Healthcare, and Apollo's Club Med buyout — deals that either delivered exceptional returns, navigated complex situations, or reshaped their industries.

Medline fits that profile not because it was the largest exit or the highest return, but because it worked when most exits didn't. In a year when IPO volumes fell to decade lows and sponsors struggled to find liquidity, Blackstone, Carlyle, and Hellman & Friedman executed a clean, institutional-quality exit that returned capital to LPs and proved that patient, operationally-focused private equity still creates value.

The award also signals a broader shift in how the industry defines success. A decade ago, Deal of the Year often went to the flashiest transaction — the biggest check, the boldest bet, the most levered structure. Today, it goes to deals that simply get done well. That's a reflection of market maturity, LP scrutiny, and the reality that in a high-rate, low-exit environment, competence beats creativity.

For the sponsors, the recognition is validation but not vindication. They still hold majority stakes in a company now subject to public market volatility, analyst scrutiny, and quarterly earnings pressure. The real test of this deal won't be the award or the IPO pricing — it'll be whether Medline can sustain margins, grow revenue, and manage its debt load in an operating environment that remains unpredictable.

As a public company, Medline faces different pressures than it did under private ownership. Quarterly earnings calls, activist investor scrutiny, and stock price volatility replace the patient capital and operational flexibility of PE sponsorship. Management must balance short-term performance expectations with long-term strategic investments — a tension that has derailed many newly public companies.

The sponsors will likely begin selling down their stakes over the next 12-24 months through secondary offerings, gradually reducing their ownership to minority positions or exiting entirely. Those sales will provide further liquidity and allow the firms to return capital to LPs, but they'll also remove the strategic oversight and operational support that drove value creation during the hold period.

If there's a playbook to extract from Medline, it's this: operational excellence still matters more than financial engineering. The sponsors didn't create value by levering up, cutting costs to the bone, or flipping the company quickly. They invested in automation, streamlined operations, made strategic acquisitions, and waited for the right exit window.

That patience is increasingly rare. In an era when LPs demand faster liquidity and GPs feel pressure to deploy capital quickly, holding a company for three years and settling for a 7-8% IRR feels almost quaint. But it worked. Medline returned capital, delivered a clean exit, and avoided the distressed scenarios that have trapped other mega-cap LBOs.

The deal also highlights the importance of sector selection. Healthcare distribution isn't flashy. It doesn't get hyped on Twitter or profiled in glossy magazines. But it's stable, essential, and resistant to technological disruption in ways that retail, media, and even some software businesses are not. Sometimes boring wins.

For other sponsors sitting on portfolio companies acquired in 2020-2022, Medline offers both hope and caution. The IPO market can open, but only for the right companies at the right price. Institutional investors will buy healthcare and industrial businesses with predictable cash flows, but they won't overpay. And patience — real patience, not just LP presentation patience — can actually pay off if the fundamentals are sound.

Medline's successful IPO hasn't gone unnoticed among competitors and other PE-backed healthcare distributors. The deal proves that institutional investors will back large-cap distribution businesses even in a challenging macro environment — if the story is right.

Competitors like McKesson, Cardinal Health, and Henry Schein are all public and have watched Medline's valuation closely. The IPO pricing suggested that investors valued Medline roughly in line with these peers on an EV/EBITDA basis, which validates the sector's multiples and could support further consolidation or public offerings in adjacent categories.

Several private equity firms are now reportedly exploring similar exit strategies for portfolio companies in adjacent healthcare services and supply chain businesses. If Medline's stock performs well over the next year, expect more sponsors to test the public markets with operationally improved, margin-expanded distribution businesses.

On the M&A side, Medline's successful transition to public markets could also spark consolidation. Smaller regional distributors and specialty product companies may become acquisition targets as public players seek to expand product lines and geographic reach. The sponsors' playbook — automate, consolidate, expand margins — is replicable, and several mid-market PE firms are already circling targets in wound care, surgical supplies, and post-acute distribution.

Medline's story is far from over. As a newly public company, it faces several near-term tests that will determine whether this exit becomes a case study in successful value creation or a cautionary tale about premature liquidity.

First, can it grow revenue at 8-10% annually without sacrificing margins? Healthcare distribution is competitive, and price pressure from hospital systems and GPOs (group purchasing organizations) is constant. If Medline's margins compress or revenue growth slows, the stock will reprice quickly.

Second, how will it manage its $18 billion debt load in a still-elevated rate environment? Interest expense is significant, and any refinancing activity over the next 18 months will be closely watched by analysts and investors. The company has options — asset sales, further equity raises, or operational deleveraging through cash flow — but all come with trade-offs.

Third, will the sponsors exit cleanly or stick around? If Blackstone, Carlyle, and Hellman & Friedman sell down their stakes too quickly, it could signal concerns about the company's public market trajectory. If they hold longer, it suggests confidence but also ties up capital that LPs expect returned.

And finally, how will Medline compete in a landscape where Amazon, digital health platforms, and AI-driven supply chain companies are all pushing into healthcare distribution? The company's moat is deep — customer relationships, scale, regulatory expertise — but it's not impenetrable. Innovation and technology investment will determine whether Medline thrives or becomes the next legacy incumbent disrupted by a faster, cheaper competitor.

In another market cycle, Medline's IPO might have felt routine. A solid business, improved operations, reasonable valuation, clean exit. But in 2024, when IPO volumes cratered and sponsors struggled to find liquidity for even their best assets, this deal was anything but ordinary.

Blackstone, Carlyle, and Hellman & Friedman took a boring, family-owned distributor, applied classic operational discipline, waited out a brutal exit market, and still got the deal done. They didn't manufacture a growth story, chase buzzwords, or rely on financial engineering. They just made the business better and found buyers willing to pay for it.

That simplicity is deceptive. Most firms can't execute it. Most exits don't work. Most IPOs get pulled or priced below expectations, leaving sponsors and LPs stuck in illiquid positions for years.

Medline worked. And in a year when almost nothing did, that alone makes it Deal of the Year.